Literature DB >> 31840243

Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature.

Dikélélé Elessa1,2, Alexis Talbot1,2, Naëlle Lombion1,2, Stéphanie Harel1,2, Lionel Galicier2,3, Agnès Veyradier2,4,5, Bérangère Joly2,4,5, Annalisa Andreoli6, Sophie Rigaudeau7, Élie Azoulay2,8, Paul Coppo4,9, Bruno Royer1,2, Bertrand Arnulf1,2.   

Abstract

Entities:  

Keywords:  ADAMTS13; lenalidomide; myeloma; thrombotic microangiopathy; thrombotic thrombocytopenic purpura

Year:  2019        PMID： 31840243     DOI： 10.1111/bjh.16333

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature.

Authors:  Vanessa Alexandra Buetler; Nada Agbariah; Deborah Pia Schild; Fabian D Liechti; Anna Wieland; Nicola Andina; Felix Hammann; Johanna A Kremer Hovinga
Journal:  Front Med (Lausanne)       Date:  2022-05-17

Review 2.  How I treat microangiopathic hemolytic anemia in patients with cancer.

Authors:  M R Thomas; M Scully
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

Review 3.  The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.

Authors:  Chanukya K Colonne; Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Healthcare (Basel)       Date:  2022-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.